Search Results - "R.T. Maziarz"

Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation by Giralt, S.A., Mangan, K.F., Maziarz, R.T., Bubalo, J.S., Beveridge, R., Hurd, D.D., Mendoza, F.L., Rubenstein, E.B., DeGroot, T.J., Schuster, M.W.

“…Explore safety and efficacy of three palonosetron-containing regimens for emesis prevention over 7 days in multiple myeloma (MM) patients receiving melphalan…”
Get full text

Autophagy and mTOR inhibition as mechanisms for combatting chemoresistance to standard chemotherapy: Final results of a phase I study of infusional cyclophosphamide (cy), pulse dexamethasone (dex), rapamycin (rapa) and hydroxychloroquine (HCQ) by Scott, E.C, Reasor-Heard, S, Floyd, K, Park, B, Trubowitz, P, Medvedova, E, Spurgeon, S.E, Smith, S.D, Kratz, A, Gordon, M, Siegel, M, Liu, S.Q, Arora, R, Loriaux, M, Stadtmauer, E, Amaravadi, R, Vogl, D.T, Maziarz, R.T

Get full text

Fully MHC-matched allogeneic hematopoietic stem cell transplantation in SIV-infected, cART-suppressed Mauritian cynomolgus macaques indicates GVHD as a reservoir clearance mechanism by H.L. Wu, B.J. Burwitz, S.A. Abdulhaqq, C. Shriver-Munsch, T. Swanson, A.W. Legasse, K.B. Hammond, J.S. Reed, M. Northrup, S.L. Junell, J.M. Greene, G.M. Webb, B.N. Bimber, W. Laub, P. Kievit, R. MacAllister, M.K. Axthelm, R. Ducore, A. Lewis, L. Colgin, T.R. Hobbs, L.D. Martin, C.R. Thomas, A. Panoskaltsis-Mortari, G. Meyers, J.J. Stanton, R.T. Maziarz, J.B. Sacha

Get full text

Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas by Ghilardi, G., Chong, E.A., Svoboda, J., Wohlfarth, P., Nasta, S.D., Williamson, S., Landsburg, J.D., Gerson, J.N., Barta, S.K., Pajarillo, R., Myers, J., Chen, A.I., Schachter, L., Yelton, R., Ballard, H.J., Hodges Dwinal, A., Gier, S., Victoriano, D., Weber, E., Napier, E., Garfall, A., Porter, D.L., Jäger, U., Maziarz, R.T., Ruella, M., Schuster, S.J.

“…Anti-CD19 chimeric antigen receptor T-cell immunotherapy (CAR-T) is now a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas; however,…”
Get full text

Long Term Engraftment Is Associated with Survival After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma by Bains, T, Lemieux, A, Abar, F, Maziarz, R.T, Chen, A.I

Get full text

Allogeneic Stem Cell Transplantation in Secondary Acute Myeloid Leukemia and Myelodysplastic Syndrome: OHSU Experience by Perets Avraham, G, Meyers, G, Kovacsovics, T, Curtin, P.T, Leis, J.F, Bains, T, Lemieux, A, Maziarz, R.T

Get full text

Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) in Chronic Lymphocytic Leukemia (CLL): Impact of Myeloablative (MA) Vs. Reduced-Intensity Conditioning (RIC) Regimens, and Impact of Total Body Irradiation (TBI)-Based MA Versus Chemotherapy (CT)-Based MA Conditioning by Leis, J.F, Sabloff, M, Sobecks, R.M, Maziarz, R.T, Ahn, K.W, Zhu, X, Kalaycio, M.E, Cortes, J, Saber, W

Get full text

Improved Outcome of Elderly Patients After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation (HCT) by Perets Avraham, G, Bains, T, Lemieux, A, Slater, S, Kovacsovics, T, Curtin, P, Gajewski, J, Meyers, G, Maziarz, R.T

Get full text

Multipotent Adult Progenitor Cells (Multistem®) Enhance Bone Marrow Recovery After Ablative Allogeneic Stem Cell Transplant by Newell, L.F, Leeborg, N, Dong, Z.M, Perets Avraham, G, Deans, R, Chauncey, T.R, Maziarz, R.T

Get full text

Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome by Lechowicz, M J, Lazarus, H M, Carreras, J, Laport, G G, Cutler, C S, Wiernik, P H, Hale, G A, Maharaj, D, Gale, R P, Rowlings, P A, Freytes, C O, Miller, A M, Vose, J M, Maziarz, R T, Montoto, S, Maloney, D G, Hari, P N

“…We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with…”
Get full text

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization by Dugan, M J, Maziarz, R T, Bensinger, W I, Nademanee, A, Liesveld, J, Badel, K, Dehner, C, Gibney, C, Bridger, G, Calandra, G

“…Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study…”
Get full text

146: Impact of Health Insurance on Time to Approval and Time to Transplant Among Patients Receiving Hematopoietic Stem Cell Transplantation by McHenry, M, Hayes-Lattin, B, Maziarz, R.T

Get full text

An Institutional Perspective on the Efficacy of Donor Leukocyte Infusions for Patients with Post-Transplant Relapse by Myers, L, Burmeister, J, Mater, E, Murray, S, Curtin, P.T, Gajewski, J.L, Hayes-Lattin, B, Kovacsovics, T, Leis, J.F, Meyers, G, Slater, S, Maziarz, R.T

Get full text

A Randomized Phase III Trial Investigating 2 Gy TBI Vs. Flu/2 Gy TBI Conditioning for HLA-Matched Related Donor Hematopoietic Cell Transplantation (HCT): Tempo of CD3 and NK Cell Engraftment Determines Relapse and Progression Free Survival in Patients with Hematologic by Kornblit, B, Storer, B, Storb, R.F, Hari, P, Vucinic, V, Maziarz, R.T, Chauncey, T, Pulsipher, M.A, Bruno, B, Petersen, F.B, Bethge, W.A, Hubel, K, Storek, J, Maloney, D.G, Sandmaier, B.M

Get full text

Prophylaxis of Acute GVHD Using Multistem® Stromal Cell Therapy: Preliminary Results After Administration of Single or Multiple Doses in a Phase 1 Trial by Maziarz, R.T, Devos, T, Bachier, C, Goldstein, S.C, Leis, J, Cooke, K.R, Perry, R, Deans, R.J, Van't Hof, W.J, Lazarus, H.M

Get full text

Immune evasion by neocartilage-derived chondrocytes: Implications for biologic repair of joint articular cartilage by Adkisson, H D, Milliman, C, Zhang, X, Mauch, K, Maziarz, R T, Streeter, P R

“…Degeneration of joint articular cartilage is a leading cause of disability worldwide, and is due in large part to the fact that adult articular cartilage is…”
Get more information

Efficacy Of Plerixafor Plus G-CSF In Hematopoietic Stem Cell (HSC) Remobilization In Patients With Amyloidosis by Micallef, I.N.M, Maziarz, R.T, van Rhee, F, Horwitz, M, Hill, J, Stewart, K, Mody, P, Huebner, D, Shaughnessy, P

Get full text

CNS Remission Predicts Survival After Autologous Hematopoietic Stem Cell Transplantation (AHCT) For Non-Hodgkin Lymphoma (NHL) With Pre-Existing CNS Involvement: A CIBMTR Analysis by Maziarz, R.T, Wang, Z, Zhang, M.-J, Laport, G.G, Lazarus, H.M, Montoto, S, Hari, P.N

Get full text

Stromal Stem Cell Therapy for Prophylaxis of Acute GVHD: Preliminary Results From a Phase 1 Trial by Maziarz, R.T, Bachier, C, Goldstein, S, Devine, S, Leis, J, Cooke, K, Perry, R, Van't Hof, W, Deans, R, Lazarus, H.M

Get full text

Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis by Khoury, H J, Kukreja, M, Goldman, J M, Wang, T, Halter, J, Arora, M, Gupta, V, Rizzieri, D A, George, B, Keating, A, Gale, R P, Marks, D I, McCarthy, P L, Woolfrey, A, Szer, J, Giralt, S A, Maziarz, R T, Cortes, J, Horowitz, M M, Lee, S J

“…Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in…”
Get full text